



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Neurology

**ESPS manuscript NO:** 14311

**Title:** Targeting Remyelination Treatment for Multiple Sclerosis

**Reviewer code:** 00664182

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-29 21:53

**Date reviewed:** 2014-10-11 03:09

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

This inviting review is very well written. The discussion of the inhibitory pathways for oligodendrocyte differentiation and remyelination after multiple sclerosis is comprehensive and thoughtful. The updated list of drugs potentially targeting these pathways provides very useful information. This review will be interesting to broad readers from basic scientists to clinicians.



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Neurology

**ESPS manuscript NO:** 14311

**Title:** Targeting Remyelination Treatment for Multiple Sclerosis

**Reviewer code:** 00646543

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-29 21:53

**Date reviewed:** 2014-10-09 06:02

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

The Review Targeting Remyelination Treatment for Multiple Sclerosis is a comprehensive and well written account on the relevant issue on brain repair in MS. I have some minor points: 1. Recent reports point out the apparent neuronal primary damage in MS, rather than the classical concept of primary demyelination. The authors should mention these thesis and how remyelination could serve as potential therapy. 2. On P4,p1,L1-3 the authors mention "several drugs", I think that there are few and most of them in the initial steps for clinical research. 3. It seems to me that the subject of "therapeutic antibodies" (P4,p2) should be placed under a separate subheadings from pharmacological substances. 4. It should receive conceptual consideration that remyelination does not signify functional recovery.